Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 14-004009
NCT ID: NCT01673711
Sponsor Protocol Number: CLN-I194611
About this study
This clinical trial studies deuterated phenanthrene tetraol in smokers who are at high risk for lung cancer. Studying samples of urine in the laboratory from smokers who are at high risk for lung cancer may help doctors learn more about biomarkers related to cancer.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Criteria:
- Current or former smoker
- 18 years of age or older
- Documentation of a diagnosis of no dysplasia, dysplasia, or metaplasia on bronchoscopy (white light and/or autofluorescence) conducted less than or equal to 10 years prior to registration
- Not pregnant, planning on becoming pregnant or breastfeeding
- Able to provide written informed consent indicating an understanding of the nature of the study
- Willing to comply with study requirements, including taking [D10]phenanthrene in water with 20% ethanol
- No previous history of aerodigestive cancer
- Not currently undergoing treatment for any cancers. Exception: basal cell or squamous cell skin cancer
- Not currently taking any other investigational agents
- No history of allergic reaction to [D10]phenanthrene or similar compounds
- No major medical comorbidities, for example, renal dysfunction, heart function, and diabetes, to be adjudicated by study physicians
- Not a former or recovering alcoholic
- No use of metronidazole
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator David Midthun, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
855-776-0015
|
More information
Publications
Publications are currently not available